Merrem, Vaborem(meropenem)
Merrem, Vabomere, Vaborem (meropenem) is a small molecule pharmaceutical. Meropenem was first approved as Merrem on 1996-06-21. It is used to treat appendicitis, bacterial infections, bacteroides infections, escherichia coli infections, and fever amongst others in the USA. It has been approved in Europe to treat bacteremia, bacterial infections, pneumonia, respiratory tract infections, and urinary tract infections amongst others.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
Merrem (generic drugs available since 2011-10-26)
CombinationsVabomere
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| appendicitis | EFO_0007149 | D001064 | K37 |
| bacterial infections | — | D001424 | A49 |
| bacteroides infections | EFO_1000832 | D001442 | — |
| escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
| fever | HP_0001945 | D005334 | R50.9 |
| haemophilus meningitis | EFO_1000955 | D008583 | G00.0 |
| klebsiella infections | EFO_1001353 | D007710 | — |
| meningococcal meningitis | EFO_1001040 | D008585 | A39.0 |
| neutropenia | — | D009503 | D70 |
| peritonitis | EFO_0008588 | D010538 | K65 |
Show 5 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MEROPENEM / VABORBACTAM, VABOMERE, REMPEX | |||
| 2027-08-29 | GAIN | ||
| 2022-08-29 | NCE | ||
Clinical
Clinical Trials
138 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | 1 | 2 | 11 | 1 | — | 15 |
| Sepsis | D018805 | A41.9 | — | 2 | 5 | 4 | 4 | 13 | |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | — | 7 | 1 | 1 | 9 |
| Infections | D007239 | EFO_0000544 | 1 | 2 | 3 | 1 | 2 | 8 | |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | 2 | 2 | 3 | 8 |
| Bacterial infections | D001424 | A49 | 3 | — | 1 | 3 | 1 | 8 | |
| Septic shock | D012772 | A48.3 | 1 | 1 | 3 | 1 | 2 | 7 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | 3 | 3 | 6 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 3 | 2 | 1 | 6 |
| Critical illness | D016638 | — | 1 | — | 1 | 4 | 6 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 2 | 8 | — | — | 10 |
| Intraabdominal infections | D059413 | 1 | 5 | 5 | — | — | 10 | ||
| Healthcare-associated pneumonia | D000077299 | — | — | 4 | — | — | 4 | ||
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 1 | — | 1 | 2 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | 2 | — | — | 2 |
| Neonatal sepsis | D000071074 | HP_0040187 | — | — | 1 | — | 1 | 2 | |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 1 | 1 | — | — | 2 |
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | 1 | — | 1 | 2 |
| Ascites | D001201 | HP_0001541 | R18 | — | 1 | 1 | — | — | 1 |
| Iatrogenic disease | D007049 | — | — | 1 | — | — | 1 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melioidosis | D008554 | A24.9 | — | 1 | — | — | 1 | 2 | |
| Cross infection | D003428 | — | 1 | — | — | 1 | 2 | ||
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 2 | — | — | — | 2 |
| Communicable diseases | D003141 | — | 1 | — | — | — | 1 | ||
| Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | 1 | — | — | — | 1 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | 1 | — | — | — | 1 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | 1 | 1 | — | — | — | 1 |
| Meningitis | D008581 | EFO_0000584 | G03 | 1 | 1 | — | — | — | 1 |
| Necrotizing enterocolitis | D020345 | EFO_0003928 | K55.3 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Inflammation | D007249 | 1 | — | — | — | — | 1 | ||
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | — | — | 2 | 2 | ||
| Chronic bronchitis | D029481 | J42 | — | — | — | — | 1 | 1 | |
| Bacterial meningitis | D016920 | EFO_1000831 | G00 | — | — | — | — | 1 | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 | ||
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | — | — | — | — | 1 | 1 |
| Drug monitoring | D016903 | — | — | — | — | 1 | 1 | ||
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Alcoholic hepatitis | D006519 | EFO_1001345 | K70.1 | — | — | — | — | 1 | 1 |
| Lung transplantation | D016040 | — | — | — | — | 1 | 1 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | MEROPENEM |
| INN | meropenem |
| Description | Meropenem is a carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively. It has a role as an antibacterial drug, an antibacterial agent and a drug allergen. It is a carbapenemcarboxylic acid, a pyrrolidinecarboxamide, an alpha,beta-unsaturated monocarboxylic acid and an organic sulfide. |
| Classification | Small molecule |
| Drug class | antibacterial antibiotics, carbapenem derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 96036-03-2 |
| RxCUI | 1546029 |
| ChEMBL ID | CHEMBL127 |
| ChEBI ID | 43968 |
| PubChem CID | 441130 |
| DrugBank | DB00760 |
| UNII ID | YOP6PX0BAO (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Merrem - AstraZeneca
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 35,412 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,397 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more